



## ORIGINAL ARTICLE

## Self-medication with analgesics reported by patients with ulcerative colitis: An anonymous survey



Iago Rodríguez-Lago<sup>a,\*</sup>, Francisco Mesonero<sup>b</sup>, Gonzalo Hijos-Mallada<sup>c</sup>, Mercedes Cañas<sup>d</sup>, Roberto Saldaña<sup>e</sup>, Claudia Savini<sup>e</sup>, Sabela Fernández<sup>f</sup>, Berta Juliá<sup>f</sup>, Luis Cea-Calvo<sup>f</sup>, on behalf of ACCU, GETECCU, GETEII

<sup>a</sup> Inflammatory Bowel Disease Unit, Hospital de Galdakao, Galdakao (Vizcaya), Spain

<sup>b</sup> Inflammatory Bowel Disease Unit, Ramón y Cajal University Hospital, Madrid, Spain

<sup>c</sup> Digestive Diseases Service, Clínico Lozano Blesa University Hospital, Zaragoza, Spain

<sup>d</sup> Inflammatory Bowel Disease Unit, Clínico San Carlos University Hospital, Madrid, Spain

<sup>e</sup> Spanish Confederation of Patients with Crohn's Disease and Ulcerative Colitis (ACCU), Madrid, Spain

<sup>f</sup> Medical Affairs Department, MSD, Spain

Received 13 May 2021; accepted 27 July 2021

Available online 13 August 2021

### KEYWORDS

Analgesics;  
Inflammatory bowel disease;  
Pain;  
Self-medication;  
Ulcerative colitis

### Abstract

**Introduction:** Analgesics are widely used, but evidence regarding whether their use increases the risk of inflammatory bowel disease (IBD) flares or complications is unclear. Therefore, self-medication with analgesics in IBD is usually not recommended. The aim of this study was to explore the prevalence of self-medication with analgesics in a cohort of ulcerative colitis (UC) patients and to identify reasons and factors associated with self-medication.

**Methods:** This cross-sectional study included consecutive unselected adult patients with UC. Participants were asked to complete an anonymous web-based survey with multiple-choice questions and closed responses. No clinical data were collected.

**Results:** A total of 546 patients (61.2% women, mean age 39.9 years) completed the survey. The prevalence of self-medication with analgesics was 49.8% (272/546). Paracetamol (45.2%) and metamizole (21.2%) were the most frequently used drugs; frequencies of self-medication were <5% for other analgesics (nonsteroidal anti-inflammatory drugs, opioids). The most frequent reasons for self-medication were the need for quick symptom relief and that it had been agreed with/prescribed by the treating physician. Multivariable analysis identified female sex (odds ratio [OR] = 1.9), sick leave (OR = 2.2), treatment with intravenous drugs (OR = 2.9), and emergency room visit (OR = 2.3) as variables associated with self-medication, whilst follow-up by a nurse was associated with less self-medication (OR = 0.6).

\* Corresponding author.

E-mail address: [iago.r.lago@gmail.com](mailto:iago.r.lago@gmail.com) (I. Rodríguez-Lago).

**Conclusion:** The frequency of self-medication with analgesics in UC patients is high and appears to be associated with variables suggesting worse disease control. Closer follow-up, including a specialized nurse, could decrease self-medication. Strategies to improve disease control, including close monitoring of symptoms such as pain, are needed.

© 2021 The Authors. Published by Elsevier España, S.L.U. This is an open access article under the CC BY-NC-ND license (<http://creativecommons.org/licenses/by-nc-nd/4.0/>).

## PALABRAS CLAVE

Analgésicos;  
Enfermedad  
inflamatoria  
intestinal;  
Dolor;  
Automedicación;  
Colitis ulcerosa

## Automedicación con analgésicos en pacientes con colitis ulcerosa: encuesta anónima

### Resumen

**Introducción:** Los analgésicos son medicamentos ampliamente utilizados, pero las evidencias sobre si su uso aumenta el riesgo de brotes o complicaciones de la enfermedad inflamatoria intestinal (EII) no están claras; por lo tanto, en general, no se recomienda la automedicación con analgésicos en la EII. El objetivo de este estudio fue explorar la prevalencia de automedicación con analgésicos en una cohorte de pacientes con colitis ulcerosa (CU) e identificar los motivos y los factores asociados a la automedicación.

**Métodos:** En este estudio transversal se incluyeron pacientes adultos con CU consecutivos y no seleccionados. Se pidió a los participantes que completasen una encuesta anónima por Internet con preguntas de elección múltiple y respuestas cerradas. No se recogieron datos clínicos.

**Resultados:** Completaron la encuesta un total de 546 pacientes (61,2% mujeres; edad media 39,9 años). La prevalencia de automedicación con analgésicos fue del 49,8% (272/546). El paracetamol (45,2%) y metamizol (21,2%) fueron los fármacos utilizados con más frecuencia; la tasa de automedicación con otros analgésicos (antiinflamatorios no esteroideos, opioides) fue < 5%. Los motivos más frecuentes para la automedicación fueron la necesidad de alivio sintomático rápido y que había sido acordado con/prescrito por el médico responsable del tratamiento. El análisis multivariante identificó el sexo femenino (*odds ratio* [OR] = 1,9), la baja laboral (OR = 2,2), el tratamiento con fármacos intravenosos (OR = 2,9) y las visitas a urgencias (OR = 2,3) como variables asociadas a la automedicación, mientras que el seguimiento por el personal de enfermería se asoció a menos automedicación (OR = 0,6).

**Conclusión:** La frecuencia de automedicación con analgésicos en pacientes con CU es alta y parece estar asociada a variables que sugieren peor control de la enfermedad. Un seguimiento más estrecho, incluyendo personal de enfermería especializado, podría disminuir la automedicación. Se necesitan estrategias para mejorar el control de la enfermedad, incluyendo un seguimiento estrecho de síntomas como el dolor.

© 2021 Los Autores. Publicado por Elsevier España, S.L.U. Este es un artículo Open Access bajo la licencia CC BY-NC-ND (<http://creativecommons.org/licenses/by-nc-nd/4.0/>).

## Introduction

Analgesics are among the most commonly used medications worldwide. Recent data from the Spanish population, including over-the-counter acquisition, revealed a prevalence of nonsteroidal anti-inflammatory drug (NSAID) consumption of nearly 30%, with a higher frequency in women and a step-down trend with age.<sup>1</sup> Regarding other analgesics, paracetamol (27.4%) and metamizole (5.5%) are the most commonly used in the Spanish population.<sup>2</sup>

NSAID consumption, unlike paracetamol, is associated with upper and lower gastrointestinal tract damage,<sup>3,4</sup> sometimes producing lesions that may resemble inflammatory bowel disease (IBD),<sup>5</sup> and it is considered to be associated with an increased risk of IBD flares.<sup>6</sup> Moreover, the prevalence of analgesics prescriptions seems higher in IBD patients than in the general population, including both narcotic (48.1% vs 34.1%) and non-narcotic analgesics (12.8% vs 8.1%),<sup>7</sup> with a substantial additional percentage

being self-medicated.<sup>8</sup> Similarly-designed studies showed a 30–50% prevalence of NSAIDs use in IBD patients.<sup>9,10</sup> A meta-analysis of 24 studies found no association between NSAID use and the risk of IBD flares.<sup>11</sup> However, when analyzing only studies with a low risk of bias, NSAID use appeared to increase the risk of CD (relative risk [RR] 1.53, –95% CI 1.08–2.16), but not UC, flare. Contrary to expectations, paracetamol use was associated with an increased risk of IBD flares (RR 1.56, –95% CI 1.22–1.99).<sup>11</sup> Based on this evidence, current IBD guidelines state that short-term use of NSAIDs is unlikely to be detrimental, and it should be used if considered necessary, although long-duration treatments are not recommended.<sup>12,13</sup>

With regard to opioid analgesics, a Canadian study reported 5% of IBD patients became heavy opioid users within 10 years of diagnosis.<sup>14</sup> This is worrisome as opioid use is associated with high rates of serious infection and mortality,<sup>14,15</sup> and IBD guidelines recommend that long-term opioid use should be discouraged.<sup>16</sup>

Finally, evidence regarding metamizole use and risks in IBD patients is scarce, as it has been withdrawn from many markets,<sup>17</sup> but the frequency of use of this drug by IBD patients in marketed countries seems low (about 10%).<sup>18,19</sup>

To our knowledge, there are no data in Spain collected directly and anonymously from patients regarding self-medication with analgesics in UC patients. Thus, we designed a cross-sectional survey, with the aim of assessing the frequency of self-medication with corticosteroids (primary objective, information already published<sup>20</sup>) and with analgesics (secondary objective, subject of the current work) in a cohort of adult patients with UC, as well as to identify the factors associated with self-medication.

## Methods

This study was a cross-sectional, anonymous web-based survey of adult patients with UC. No data from clinical charts were collected. Patients were invited to participate by the Spanish Confederation of Associations of Patients with Crohn's Disease and Ulcerative Colitis (ACCU) and by their gastroenterology healthcare providers (either physicians or nurses) from the Spanish Working Group on Crohn's Disease and Ulcerative Colitis (GETECCU) and the Spanish Nurses Working Group on Inflammatory Bowel Disease (GETEII). Additional information on the design has been described previously.<sup>20</sup> The study was approved by the Clinical Research Ethics Committee of the University Hospital Ramón y Cajal, Madrid, Spain. As the survey was voluntary and anonymous, completion of the survey was considered as implied patient consent to participate; this was approved by the Clinical Research Ethics Committee.

The survey was composed of multiple-choice questions with closed responses (no open-text questions were included) on patients' demographics, patients' perceptions of UC burden, characteristics of healthcare received and on self-medication. Subject recall for all survey questions was within the past year. To assess self-medication with analgesics, patients responded with "Yes" or "No" to the question "During the past year, have you started treatment with analgesics by your own initiative for treating the pain related to ulcerative colitis?". A list of the most frequent therapies used for pain relief in Spain was provided.

Quantitative variables are expressed as mean and standard deviation (SD), or median and interquartile range (IQR) and qualitative variables as frequencies or percentages. Comparisons of the frequency of self-medication were performed using the  $\chi^2$ -test or Fisher exact test. A logistic regression model was developed to assess variables associated with self-medication; age, gender and variables with  $p$  values  $< 0.05$  in the bivariate analysis were included in the model. Odds Ratio (OR) and 95% confidence intervals (CI) are provided.

## Results

From February to April 2019, 546 patients completed the survey: 212 men (38.8%) and 334 women (61.2%), with a mean age of 39.9 years [SD 11.9] and a median duration of UC since diagnosis of 7 years. A total of 272 patients (49.8%) reported self-medication with analgesics during the past

year by responding "yes" to the above-mentioned question. Self-medication was more frequent with paracetamol and metamizole (Fig. 1); frequencies were  $< 5\%$  for other analgesics including NSAIDs and opioid derivatives.

Self-medication with analgesics was reported more frequently by women than men (56.0% vs 40.1%,  $p < 0.001$ ), and was less frequent in the upper quartile of age (49 years or more, Table 1). The frequency was similar in patients with UC duration above or below the median. The frequency did not differ significantly among patients with different educational degrees. Patients on sick leave reported a higher frequency of self-medication (75.5%) than those actively working (47.3%), unemployed (51.3%) housekeeping (56.3%) or than students (52.0%) ( $p = 0.003$ ).

With regard to patients' perception of disease activity, the frequency of self-medication with analgesics ranged from 39.2% in patients who considered their UC as mostly inactive during the past year, to 65.1% in those who described it as severe ( $p < 0.001$ ). Patients who had needed urgent telephone assistance or at least one emergency room visit due to UC activity, reported a higher frequency of self-medication (Table 1).


The frequency of self-medication was similar in patients followed-up in a general gastroenterology clinic or in an IBD unit (47.1% and 50.7% respectively,  $p = 0.815$ ). Those with four or more medical appointments per year, who did not have the option to contact their gastroenterology healthcare providers via e-mail or telephone, or who did not have follow-up by a specialized nurse at the clinic, reported higher frequency of self-medication (Table 1). Some 77 of 117 patients (65.8%) who were being treated with intravenous biological medications compared with 170 of 429 (39.6%) of those who were not ( $p < 0.001$ ) declared self-medication with analgesics. There were no differences with in self-medication in those being treated with subcutaneous biological drugs (50.9% versus 49.8% in those not treated with subcutaneous biologicals,  $p = 0.976$ ).

The most common reasons for self-medication were "the need for quick relief of symptoms" and "it had been agreed with or prescribed in the past by the treating physician" (Table 2).

The multivariable model included, as independent variables, age, gender, employment status, number of regular UC-related medical appointments per year, disease activity, need of telephone assistance, emergency room visit, access by e-mail or telephone contact, access to specialized nurse and treatment with intravenous biological therapies. Female sex (OR = 1.9 [95% CI: 1.3–2.8],  $p < 0.001$ ), sick leave (OR = 2.2 [1.1–4.6],  $p = 0.031$ ), treatment with intravenous drugs (OR = 2.9 [1.8–4.6],  $p < 0.001$ ), and emergency room visit (OR = 2.3 [1.5–3.6],  $p < 0.001$ ), were variables positively associated with self-medication with analgesics, whilst access to a specialized nurse vs no access was associated with less self-medication (OR = 0.6 [0.4–0.9],  $p = 0.022$ ).

## Discussion

This study reaffirms the fact that, although guidelines do not recommend self-medication with analgesics in IBD patients, the use of these drugs without indication by the treating



**Figure 1** Frequency of self-medication with specific analgesics.

**Table 1** Frequency of self-medication by different demographic and disease-related variables. Bivariate analysis.

	Frequency, n (%)	p
<b>Sex</b>		
Male (n = 212)	85 (40.1)	<0.001
Female (n = 334)	187 (56.0)	
<b>Age (quartiles)</b>		
Q1 ( $\leq 31$ years; n = 146)	78 (53.4)	0.053
Q2 (32–39 years; n = 130)	71 (54.6)	
Q3 (40–48 years; n = 145)	74 (51.0)	
Q4 ( $\geq 49$ years, n = 125)	49 (39.2)	
<b>Perception of disease activity</b>		
Mostly inactive (n = 125)	49 (39.2)	<0.001
Mild (n = 188)	85 (45.2)	
Moderate (n = 170)	97 (57.1)	
Severe (n = 63)	41 (65.1)	
<b>Number of regular medical appointments per year for UC</b>		
Once a year (n = 102)	46 (45.1)	0.021
Two-three times per year (n = 214)	95 (44.4)	
Four or more times (n = 211)	123 (58.3)	
No regular scheduled medical appointments (n = 18)	8 (44.4)	
<b>Needed telephone assistance</b>		
No (n = 309)	133 (43.0)	<0.001
Yes (n = 237)	139 (58.6)	
<b>Needed emergency room visit</b>		
No (n = 417)	184 (44.1)	<0.001
Yes (n = 129)	88 (68.2)	
<b>Needed hospital admission</b>		
No (n = 490)	238 (48.8)	0.114
Yes (n = 56)	34 (60.7)	
<b>Access by e-mail or telephone contact</b>		
Yes (n = 413)	206 (49.9)	0.009
No (n = 75)	46 (61.3)	
Not known (n = 58)	20 (34.5)	
<b>Access to specialized nurse</b>		
Yes (n = 250)	123 (49.2)	0.010
No (n = 149)	88 (59.1)	
Not known (n = 147)	61 (41.5)	

**Table 2** Reasons for self-medication with analgesics.<sup>a</sup>

Which were the reasons for initiating analgesics by your own initiative for treating the pain related with your ulcerative colitis?	n (%)
The need for quick relief of symptoms	173 (63.6)
It had been agreed with my physician <sup>b</sup>	96 (35.3)
My doctor had prescribed analgesics in the past	83 (30.5)
Difficulty obtaining an early appointment with my physician	40 (14.7)
Fear that symptoms could worsen	38 (13.9)
It is what I am used to doing, I do not need to ask my physician	27 (9.9)
Being on vacation	14 (5.1)
Lack of time to attend the clinic	13 (4.7)
I read it on the Internet	1 (0.4)

<sup>a</sup> Patients were allowed to select more than one response; percentages were calculated over the number of patients who reported self-medication with analgesics ( $n = 272$ ).

<sup>b</sup> Agreed with my physician: recommended in the past by the physician if symptoms appear, but in this case, it was used without his/her prescription or supervision.

physician for treating UC-related pain is frequent in this population. In this anonymous survey, about half the patients declared that they had self-medicated with analgesics in the past year due to pain that they considered to be related to UC. The finding is worrisome for two reasons: (1) the potential for analgesics to partially mask UC flares, which can complicate the disease course and lead to complications, and (2) the use of drugs with relatively common adverse effects, or even some (e.g. several NSAIDs) could be contraindicated in some patients.

Paracetamol was the most common analgesic with which our cohort declared to have self-medicated (45.2%), consistent with the findings from other studies.<sup>8,18</sup> Metamizole was the second most common drug (21.2%), probably related to its wide use in the Spanish population,<sup>2,22</sup> and its better gastrointestinal toxicity profile compared with NSAIDs.<sup>23</sup> Of note, although self-medication with drugs which possess the potential for more serious adverse events (opioid derivatives and NSAIDs) was much less frequent in our cohort, efforts are still needed to reduce self-medication with these analgesics.

As observed in the general Spanish population, the use of analgesics in our cohort was higher in women and in younger patients.<sup>1</sup> Female sex was one of the factors associated with higher analgesic self-medication after multivariable analysis, in line with findings from other studies in IBD patients.<sup>19,21</sup> This finding may be partially related to the higher prevalence of extra-intestinal manifestations, such as peripheral arthropathies and arthralgia, in women.<sup>12</sup> However, we did not collect clinical data and cannot confirm this potential association.

Other variables associated with self-medication with analgesics (sick leave, emergency room visit, treatment with intravenous drugs) appear to be related to worse control or more severe UC course, suggesting that minimizing disease activity would lead to a lower requirement for analgesics. We should emphasize the importance of follow-up by a specialized nurse as one factor associated with less self-medication in this study. The availability of an IBD nurse is associated with a reduction in hospital admissions, and emergency unit and outpatient clinic visits,<sup>23</sup> and is cost-effective for the management of IBD patients<sup>24</sup>; consequently, it is recommended in current guidelines.<sup>16</sup>

However, it should be noted that self-medication with analgesics in our cohort was high even in patients who considered their disease to be inactive (39.2%). This fact has also been reported in other studies,<sup>8,21</sup> suggesting that analgesic consumption may be a marker of mild symptomatic disease that is not in complete remission, or that patients have normalized the presence of certain symptoms in their everyday life. Further investigation is needed to ascertain whether patients with presumable quiescent IBD and analgesic consumption definitely have no underlying active disease, or if pain is related to co-existing diseases.<sup>25</sup> Nonetheless, this high prevalence of analgesic consumption highlights the burden of pain for UC patients, impacting their quality of life and their social and working habits.<sup>18,19</sup>

With regard to the reasons for self-medication, the main reason reported by patients in this survey was the need for quick symptom relief, but the percentage who declared that it had been agreed with or prescribed by their treating physician in the past was also significant. In these cases, better patient-physician communication is warranted; this has been highlighted by patients in a recent evaluation of quality of care standards,<sup>26</sup> and they should inform physicians to avoid misbehaviors with regard to the intake of analgesics.

The main limitations of the study include the cross-sectional design with no follow-up and the survey format with no clinical data collection, which precludes the establishment of strong conclusions between self-medication and specific UC characteristics or outcomes. Moreover, the study is based exclusively on the statements of the sample of patients who voluntarily agreed to answer the survey. Therefore, the sample is selected, and may not reflect the habits of all patients. Although the frequency of self-medication with NSAIDs was ~5% in our survey, patients tend to underestimate their NSAID use<sup>27</sup>; consequently, if NSAID use had been sought objectively, the actual frequency in our study may have been higher than reported. Nevertheless, the study provides relevant information on variables and reasons for self-medication which can help in establishing preventive and corrective measures. The inclusion of a large number of patients, and the anonymous nature of the survey, avoiding potential bias related to the presence of the treating physician, gives strength to the study results.

## Conclusion

The frequency of self-medication with analgesics due to UC-related pain is high and appears to be related to variables suggesting persistent symptoms or worse disease control. As a striking finding, those who described their disease as



mostly inactive also described a high frequency of self-medication, suggesting that these patients could not be truly in remission and might be normalizing the presence of pain. Efforts to achieve better close monitoring and lower pain perception in this population are needed. In this regard, the survey also suggests a benefit from multidisciplinary teams with nurse follow-up for patients with UC.

## Sources of funding/support

The study was funded by MSD Spain.

## Conflicts of interest

Iago Rodríguez-Lago: board membership (Tillots Pharma, Pfizer, Ferring, Adaclyte), payment for lectures including service on speakers' bureaus (Tillots Pharma, Pfizer, MSD, AbbVie, Takeda, Dr. Falk Pharma, Ferring, Adaclyte, and Roche).

Francisco Mesonero: payment from MSD Spain for the development of educational presentations, research funding from MSD, AbbVie, Takeda, Janssen, Ferring, Kern-Pharma, and Dr. Falk Pharma.

Gonzalo Hijos-Mallada: the author declares no conflicts of interest.

Mercedes Cañas: payment for consultancy from MSD Spain.

Roberto Saldaña: the author declares no conflicts of interest.

Claudia Savini: the author declares no conflicts of interest.

Sabela Fernández: full-time employee, Medical Affairs, MSD Spain.

Berta Juliá: full-time employee, Medical Affairs, MSD Spain.

Luis Cea-Calvo: full-time employee, Medical Affairs, MSD Spain.

## Acknowledgments

The current study was funded by MSD Spain, a subsidiary of Merck & Co. Inc, Kenilworth, New Jersey, USA, and was endorsed by the Spanish Confederation of Associations of Patients with Crohn's Disease and Ulcerative Colitis (ACCU), the Spanish Working Group on Crohn's Disease and Ulcerative Colitis (GETECCU) and the Spanish Nurses Working Group on Inflammatory Bowel Disease (GETEII). The authors thank David P. Figgitt PhD, ISMPP CMPP™, Content Ed Net, for providing editorial support, with funding from MSD Spain.

## References

- Gómez-Acebo I, Dierssen-Sotos T, de Pedro M, Pérez-Gómez B, Castaño-Vinyals G, Fernández-Villa T, et al. Epidemiology of non-steroidal anti-inflammatory drugs consumption in Spain. The MCC-Spain study. *BMC Public Health*. 2018;18:1134, <http://dx.doi.org/10.1186/s12889-018-6019-z>, 2018/09/23.
- Agencia Española de Medicamentos y Productos Sanitarios - Medicamentos de Uso Humano - Observatorio del Uso de Medicamentos de la AEMPS - Informes publicados. Available from: [https://www.aemps.gob.es/medicamentos-](https://www.aemps.gob.es/medicamentos-de-uso-humano/observatorio-de-uso-de-medicamentos-utilizacion-de-medicamentos-analgescos-no-opioides-en-espana-durante-el-periodo-2010-2018/)

- [de-uso-humano/observatorio-de-uso-de-medicamentos-utilizacion-de-medicamentos-analgescos-no-opioides-en-espana-durante-el-periodo-2010-2018/](https://www.aemps.gob.es/medicamentos-de-uso-humano/observatorio-de-uso-de-medicamentos-utilizacion-de-medicamentos-analgescos-no-opioides-en-espana-durante-el-periodo-2010-2018/) [accessed 28.09.20].
- Sostres C, Gargallo CJ, Lanás A. Nonsteroidal anti-inflammatory drugs and upper and lower gastrointestinal mucosal damage. *Arthritis Res Ther*. 2013;15 Suppl. 3:S3, <http://dx.doi.org/10.1186/ar4175>.
- Watanabe T, Fujiwara Y, Chan FKL. Current knowledge on non-steroidal anti-inflammatory drug-induced small-bowel damage: a comprehensive review. *J Gastroenterol*. 2020;55:481–95, <http://dx.doi.org/10.1007/s00535-019-01657-8>.
- Vinsard DG, Stark ME, Lewis JT, Wang MH. Nonsteroidal anti-inflammatory drug-induced protein-losing enteropathy: a great masquerade of Crohn's disease. *Gastrointest Endosc*. 2017;86:1180–1, <http://dx.doi.org/10.1016/j.gie.2017.05.017>.
- Ananthakrishnan AN, Bernstein CN, Iliopoulos D, Macpherson A, Neurath MF, Ali RAR, et al. Environmental triggers in IBD: a review of progress and evidence. *Nat Rev Gastroenterol Hepatol*. 2018;15:39–49, <http://dx.doi.org/10.1038/nrgastro.2017.136>.
- Buckley JP, Kappelman MD, Allen JK, Van Meter SA, Cook SF. The burden of comedication among patients with inflammatory bowel disease. *Inflamm Bowel Dis*. 2013;19:2725–36, <http://dx.doi.org/10.1097/01.MIB.0000435442.07237.a4>.
- Long MD, Kappelman MD, Martin CF, Chen W, Anton K, Sandler RS. Role of nonsteroidal anti-inflammatory drugs in exacerbations of inflammatory bowel disease. *J Clin Gastroenterol*. 2016;50:152–6, <http://dx.doi.org/10.1097/mcg.0000000000000421>.
- Bernstein CN, Singh S, Graff LA, Walker JR, Miller N, Cheang M. A prospective population-based study of triggers of symptomatic flares in IBD. *Am J Gastroenterol*. 2010;105:1994–2002, <http://dx.doi.org/10.1038/ajg.2010.140>.
- Bonner GF, Fakhri A, Vennamaneni SR. A long-term cohort study of nonsteroidal anti-inflammatory drug use and disease activity in outpatients with inflammatory bowel disease. *Inflamm Bowel Dis*. 2004;10:751–7, <http://dx.doi.org/10.1097/00054725-200411000-00009>.
- Moninuola OO, Milligan W, Lochhead P, Khalili H. Systematic review with meta-analysis: association between acetaminophen and nonsteroidal anti-inflammatory drugs (NSAIDs) and risk of Crohn's disease and ulcerative colitis exacerbation. *Aliment Pharmacol Ther*. 2018;47:1428–39, <http://dx.doi.org/10.1111/apt.14606>.
- Harbord M, Annesse V, Vavricka SR, Allez M, Barreiro-de Acosta M, Boberg KM, et al. The first European evidence-based consensus on extra-intestinal manifestations in inflammatory bowel disease. *J Crohns Colitis*. 2016;10:239–54, <http://dx.doi.org/10.1093/ecco-jcc/jjv213>.
- Maaser C, Langholz E, Gordon H, Burisch J, Ellul P, Ramirez VH, et al. European Crohn's and colitis organisation topical review on environmental factors in IBD. *J Crohns Colitis*. 2017;11:905–20, <http://dx.doi.org/10.1093/ecco-jcc/jjw223>.
- Targownik LE, Nugent Z, Singh H, Bugden S, Bernstein CN. The prevalence and predictors of opioid use in inflammatory bowel disease: a population-based analysis. *Am J Gastroenterol*. 2014;109:1613–20, <http://dx.doi.org/10.1038/ajg.2014.230>.
- Lichtenstein GR, Feagan BG, Cohen RD, Salzberg BA, Diamond RH, Price S, et al. Serious infection and mortality in patients with Crohn's disease: more than 5 years of follow-up in the TREAT™ registry. *Am J Gastroenterol*. 2012;107:1409–22, <http://dx.doi.org/10.1038/ajg.2012.218>.
- Lamb CA, Kennedy NA, Raine T, Hendy PA, Smith PJ, Limdi JK, et al. British Society of Gastroenterology consensus guidelines on the management of inflammatory bowel disease in adults. *Gut*. 2019;68:s1–106, <http://dx.doi.org/10.1136/gutjnl-2019-318484>.

17. Dipyrrone. *Drugs and Lactation Database (LactMed)*. Bethesda (MD): National Library of Medicine (US), 2006.
18. Zeitz J, Ak M, Müller-Mottet S, Scharl S, Biedermann L, Fournier N, et al. Pain in IBD patients: very frequent and frequently insufficiently taken into account. *PLOS ONE*. 2016;11:e0156666, <http://dx.doi.org/10.1371/journal.pone.0156666>.
19. Schirbel A, Reichert A, Roll S, Baumgart DC, Büning C, Wittig B, et al. Impact of pain on health-related quality of life in patients with inflammatory bowel disease. *World J Gastroenterol*. 2010;16:3168–77, <http://dx.doi.org/10.3748/wjg.v16.i25.3168>.
20. Mesonero F, Juliá B, Saldaña R, Savini C, Cañas M, Cea-Calvo L, et al. Self-medication with oral corticosteroids reported by patients with ulcerative colitis: characteristics, reasons and patients' behaviors. *Eur J Gastroenterol Hepatol*. 2021;33:501–7, <http://dx.doi.org/10.1097/MEG.0000000000001931>.
21. Coates MD, Lahoti M, Binion DG, Szigethy EM, Regueiro MD, Bielefeldt K. Abdominal pain in ulcerative colitis. *Inflamm Bowel Dis*. 2013;19:2207–14, <http://dx.doi.org/10.1097/MIB.0b013e31829614c6>.
22. Andrade S, Bartels DB, Lange R, Sandford L, Gurwitz J. Safety of metamizole: a systematic review of the literature. *J Clin Pharm Ther*. 2016;41:459–77, <http://dx.doi.org/10.1111/jcpt.12422>.
23. Leach P, De Silva M, Mountifield R, Edwards S, Chitti L, Fraser RJ, et al. The effect of an inflammatory bowel disease nurse position on service delivery. *J Crohns Colitis*. 2014;8:370–4, <http://dx.doi.org/10.1016/j.crohns.2013.09.018>.
24. Molander P, Jussila A, Toivonen T, Mäkkeli P, Alho A, Kolho KL. The impacts of an inflammatory bowel disease nurse specialist on the quality of care and costs in Finland. *Scand J Gastroenterol*. 2018;53:1463–8, <http://dx.doi.org/10.1080/00365521.2018.1541477>.
25. Halpin SJ, Ford AC. Prevalence of symptoms meeting criteria for irritable bowel syndrome in inflammatory bowel disease: systematic review and meta-analysis. *Am J Gastroenterol*. 2012;107:1474–82, <http://dx.doi.org/10.1038/ajg.2012.260>.
26. Calvet X, Saldaña R, Carpio D, Mínguez M, Vera I, Juliá B, et al. Improving quality of care in inflammatory bowel disease through patients' eyes: IQCARO project. *Inflamm Bowel Dis*. 2020;26:782–91, <http://dx.doi.org/10.1093/ibd/izz126>.
27. Lanás A, Sekar MC, Hirschowitz BI. Objective evidence of aspirin use in both ulcer and nonulcer upper and lower gastrointestinal bleeding. *Gastroenterology*. 1992;103:862–9, [http://dx.doi.org/10.1016/0016-5085\(92\)90018-t](http://dx.doi.org/10.1016/0016-5085(92)90018-t).